SC Infrastructure Research Training Innovation, Department of Integrated Activities Research Innovation, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria.
City of Alessandria Clinic Monza Polyclinic, Alessandria.
Arch Ital Urol Androl. 2022 Mar 29;94(1):75-79. doi: 10.4081/aiua.2022.1.75.
La Peyronie's disease tends to be underdiagnosed and undertreated. In Italy it affects about 7% of the population aged between 50 and 70 years old. The aim of this study is to evaluate the quality of life of patients undergoing iontophoretic therapy with verapamil and treatment outcomes at a two-year interval.
This study evaluated 128 patients subjected to treatment cycles over a period of two years. Questionnaires were administered to the patients at the beginning and end of each cycle of iontophoretic therapy in order to monitor the degree of presumed anxiety, depression, pain and the associated quality of life.
This prospective descriptive observational study included 128 patients aged between 42 and 74 years presenting pain during erection and/or coital intercourse, which ceased in 108 cases, diminished in 12 and remained present in 4. Concerning the penile deviation, which was present in all patients (128 cases), it disappeared in 6 cases, regressed in 90 cases, while it remained unchanged in 32 cases. As for the plaque consistency on palpation, in 42 patients the plaque was no longer present, in 50 cases the consistency diminished, while in 36 patients it remained unchanged. None of the cases evidenced an aggravation of the clinical condition. 57% of the evaluated patients had high levels of anxiety in the first cycle of iontophoretic sessions and low levels of depression. Anxiety decreased in 32% of cases. Depression was not related to pain but to sexual dysfunction. About 80 % of the patients assessed had an increase in quality of life at the end of the two-year follow-up.
In conclusion, it can be claimed that iontophoresis combined with verapamil therapy can improve patients' quality of life and offer them psychophysical well-being and an acceptable sexual relationship, thus decreasing anxiety and depression levels.
佩罗尼氏病往往被漏诊和治疗不足。在意大利，50 岁至 70 岁人群中约有 7%受其影响。本研究旨在评估维拉帕米离子电渗疗法治疗两年后患者的生活质量和治疗结果。
本研究评估了 128 名接受为期两年治疗周期的患者。在每个离子电渗治疗周期开始和结束时，向患者发放问卷，以监测假定的焦虑、抑郁、疼痛程度以及相关生活质量。
本前瞻性描述性观察研究纳入了 128 名年龄在 42 岁至 74 岁之间的患者，他们在勃起和/或性交时出现疼痛，其中 108 例疼痛消失，12 例疼痛减轻，4 例疼痛持续存在。128 例患者均存在阴茎弯曲，其中 6 例消失，90 例好转，32 例无变化。触诊时斑块硬度，42 例斑块不再存在，50 例硬度减轻，36 例无变化。无病例出现病情恶化。第一个离子电渗治疗周期，57%的患者有较高的焦虑水平和较低的抑郁水平。32%的病例焦虑水平下降。抑郁与疼痛无关，而与性功能障碍有关。大约 80%的患者在两年随访结束时生活质量提高。
综上所述，维拉帕米离子电渗疗法可以改善患者的生活质量，为其提供心理和生理上的健康和可接受的性关系，从而降低焦虑和抑郁水平。
